Endothelial Graft Injector Versus Folding Forceps Insertion During Descemet's Stripping Endothelial Keratoplasty (DSEK)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Corneal Transplantation
- Sponsor
- Ocular Systems, Inc.
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- 6-month post-operative endothelial cell density
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine whether the surgical outcomes in patients undergoing Descemet's Stripping Endothelial Keratoplasty (DSEK) are improved with the use of an insertion device over the traditional forceps insertion method.
Detailed Description
Laboratory studies and clinical functionality tests have shown that the study device safely forms the tissue without creasing or folding. It allows the allograft tissue to safely pass into the anterior chamber without compression, crushing, or squeezing the endothelial cells. The device provides continuous irrigation into the eye to prevent collapse of the anterior chamber during insertion. Our study will focus on the safety and efficacy of the novel instrument over the current method of insertion (forceps). FDA has classified the device as Class I, Reserved.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Fuchs endothelial dystrophy or bullous keratopathy determined to need a corneal transplant for visual restoration.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
6-month post-operative endothelial cell density
Time Frame: 6-months post-operatively
Secondary Outcomes
- 12-month post-operative endothelial cell density(12-months post-operatively)